MoneyToday will hold the “2nd MoneyToday-MT Bio Forum” at 2:30 p.m. on Tuesday at Seoul Yeouido FKI Tower. About 100 government institutional investors and officials from pharmaceutical and biotech companies will gather to discuss strategies for the global growth of K-Bio.
The event is expected to serve as a platform for broadly exploring practical action strategies for domestic pharmaceutical and biotech companies to grow in the global market.
The theme is “K-bio, Conditions for Global Growth.” Leading domestic pharmaceutical and biotech companies will attend to directly share their experiences and know-how in entering the global market. Themed lectures will center on the cases of SK Biopharmaceuticals and Hanmi Pharmaceutical, drawing significant attention.
SK Biopharmaceuticals is enhancing the stature of K-bio by expanding prescriptions for its new epilepsy drug “Xcopri” in the United States. As a leading domestic biotech company specializing in new drug development, there is also considerable interest in its strategy for entering the global market with subsequent pipelines.
Hanmi Pharmaceutical is a representative domestic pharmaceutical company that recently obtained product approval for its homegrown obesity treatment “Epe” and has successfully commercialized various pipelines globally. The company plans to focus on introducing how it utilizes AI in the new drug development process.
The forum will also feature a themed lecture by Hwang Man-soon, CEO of Korea Investment Partners, who is regarded as one of the leading biotech investors in the country. He will introduce investment attraction know-how and growth strategies for biotech companies from the perspective of an external investor.
The Financial Supervisory Service will present improvement plans for public disclosure and communication guidelines for pharmaceutical and biotech companies, while the Ministry of Food and Drug Safety will announce its plan to support the commercialization of drugs in the development stage.
Through five themed presentations and a Q&A session with forum attendees, the event is set to be a meaningful occasion for lively discussions on practical strategies and solutions for K-bio’s growth in the global market.
In addition, congratulatory remarks will be delivered by representatives of the National Assembly, government institutional investors, and industry figures who wish for the growth of Korea’s pharmaceutical and biotech industries.
This forum is supported by the Ministry of Health and Welfare, the Ministry of Food and Drug Safety, the Korea Health Industry Development Institute, and the Korea Pharmaceutical & Biopharmaceutical Industry Association. Attendees include government officials and representatives from pharmaceutical and biotech companies who have applied for pre-registration.
MoneyToday said, "As competition for dominance in the global pharmaceutical market intensifies, K-bio appears to be at a crossroads, facing a critical choice between making a major leap forward and falling behind. It faces the important task of building a firm position in the global blockbuster drug market, with annual sales exceeding 1 trillion won, on the strength of its biopharmaceutical contract development and manufacturing (CDMO) and biosimilar businesses."
It added, "We hope the 2nd MT Bio Forum will help develop strategies for the global growth of K-bio, a key industry of the future."
in THEBIO
